Moolec Science SA Form 6-K Summary
Business Context and Reporting Period
Moolec Science SA, a Luxembourg foreign private issuer, filed this Form 6-K on April 17, 2023, for the month of April 2023. The filing reports entry into an equity subscription line with Nomura Securities International, Inc. on April 14, 2023.
Financing Terms and Key Metrics
- Aggregate financing capacity: Up to $50 million in gross proceeds from newly issued ordinary shares.
- Term: The Company may direct purchases during the 36-month period beginning on the Commencement Date, subject to effectiveness of the resale registration statement and other conditions.
- Pricing: Shares will generally be sold at a 5.0% discount to the applicable volume-weighted average price. The Company may establish a floor price for determining VWAP.
- Purchase limitations: Each purchase is limited to the greater applicable constraints described in the agreement, including no more than 20% of trading volume during the purchase period or 1 million shares.
- Ownership limitation: Nomura is not required to purchase shares if doing so would cause it and its affiliates to beneficially own more than 4.99% of the Company’s outstanding ordinary shares.
- Proceeds: The Company currently expects to use any net proceeds for working capital and general corporate purposes, but has not specified the allocation.
- Reported financial results: The filing does not provide revenue, profit, cash flow, margins, debt, liquidity balances, or other operating financial metrics.
Material Changes and Dilution Considerations
The arrangement provides a potential source of equity capital but does not require the Company to sell any shares. The Company controls the timing and amount of sales and may sell all, some, or none of the available shares. Any issuance could dilute existing shareholders, with the extent dependent on the number and price of shares sold.
The Company states that, under applicable Luxembourg law, shareholder approval is not required for issuances exceeding 20% of outstanding capital. The agreement nevertheless imposes per-purchase volume and share limits.
Outlook, Risks, and Unusual Items
- The financing is contingent on, among other matters, the SEC declaring effective an Initial Resale Registration Statement and the filing of a related final prospectus.
- Sales will depend on market conditions, the trading price of the ordinary shares, and the Company’s decisions regarding its financing needs.
- The net proceeds may be used for purposes that do not improve operating results or increase the value of the ordinary shares.
- During the agreement term, the Company is generally prohibited from entering into certain variable-rate transactions. Additional restrictions apply to private securities offerings between delivery of a purchase notice and the following trading day after share delivery.
- The agreement automatically terminates upon the earliest of expiration of the 36-month period, Nomura purchasing the full $50 million aggregate amount, loss of the Company’s listing on a principal market, or specified bankruptcy-related events.
- The Company may terminate the agreement after the Commencement Date without cost or penalty upon three trading days’ notice. Nomura may terminate upon certain customary events with the same notice period.
Investor Verification Items
- Confirm whether and when the Initial Resale Registration Statement became effective and the Commencement Date occurred.
- Verify the number and prices of any shares subsequently issued to Nomura and the remaining availability under the $50 million aggregate limit.
- Assess potential shareholder dilution and the Company’s remaining liquidity and capital requirements.
- Review the full Nomura Purchase Agreement and Registration Rights Agreement filed as Exhibits 99.1 and 99.2.
- Confirm the ultimate use of any proceeds and whether the financing affected the Company’s operating plans or capital structure.